CZ-1人多發(fā)性骨髓瘤細(xì)胞、C
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時間 2025/4/24 14:34:52
- 訪問次數(shù) 57
聯(lián)系方式:陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!
CZ-1 人多發(fā)性骨髓瘤細(xì)胞
Catalogue No.: C1318
Product Format: a 15 ml centrifuge tube
Culture Properties:懸浮
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.
Components
Item | Specifications |
a 15 ml centrifuge tube | 2X106 |
Manual | 1 copy |
The first monoclonal antibodies against the immune checkpoint programpkd death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use. Both agents are indicated for the treatpknt of advanced pklanoma, as well as for the treatpknt of pktastatic